| Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase. | |
| | |
MedLine Citation:
|
PMID: 10618707 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Telomere shortening may be one of several factors that contribute to the onset of senescence in human cells. The p53 and pRb pathways are involved in the regulation of cell cycle progression from G1 into S phase and inactivation of these pathways leads to extension of life span. Short dysfunctional telomeres may be perceived as damaged DNA and may activate these pathways, leading to prolonged arrest in G1, typical of cells in senescence. Inactivation of the p53 and pRb pathways, however, does not lead to cell immortalization. Cells that overcome senescence and have an extended life span continue to lose telomeric DNA and subsequently enter a second phase of growth arrest termed 'crisis'. Forced expression of telomerase in human cells leads to the elongation of telomeres and immortalization. The development of human cancer is frequently associated with the inactivation of the pRb and p53 pathways, attesting to the importance of senescence in restricting the tumor-forming ability of human cells. Cancer cells must also maintain telomere length and, in the majority of cases, this is associated with expression of telomerase activity. |
| | |
Authors:
|
H Vaziri; S Benchimol |
Related Documents
:
|
15661887 - The pathway of antigen uptake and processing dictates mhc class ii-mediated b cell surv... 19211137 - Induction of senescence by progesterone receptor-b activation in response to camp in ov... 9673357 - Telomere length, telomerase activity and telomerase rna expression in human esophageal ... 1168217 - The distribution of uterine glycogen during early pregnancy in the young and senescent ... 23361057 - Cytosine-based nucleoside analogs are selectively lethal to dna mismatch repair-deficie... 22941407 - Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squam... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Oncogene Volume: 18 ISSN: 0950-9232 ISO Abbreviation: Oncogene Publication Date: 1999 Dec |
Date Detail:
|
Created Date: 2000-01-14 Completed Date: 2000-01-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8711562 Medline TA: Oncogene Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 7676-80 Citation Subset: IM |
Affiliation:
|
Stanford University School of Medicine, Department of Molecular Pharmacology, Edward's Building, 300 Pasteur Drive Stanford, California, CA 94305-5332, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cell Aging* Cell Cycle DNA Damage / genetics Genome Humans Neoplasms / enzymology, genetics, pathology Retinoblastoma Protein / metabolism* Signal Transduction Telomerase / antagonists & inhibitors, metabolism* Telomere / chemistry, genetics, metabolism Tumor Suppressor Protein p53 / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Retinoblastoma Protein; 0/Tumor Suppressor Protein p53; EC 2.7.7.49/Telomerase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanisms of switching on p53: a role for covalent modification?
Next Document: mdm2: a bridge over the two tumour suppressors, p53 and Rb.